Researcher
Xavier Saelens
- Keywords (Ghent University):antiviral immunity, virology, vaccines
- Disciplines (Flanders Institute for Biotechnology):Analytical biochemistry, Cell death and senescence, Analysis of next-generation sequence data, General diagnostics
- Disciplines (Ghent University):Applied immunology, Drug discovery and development not elsewhere classified, Clinical trials, Biopharmaceuticals, In vitro testing, Non-clinical studies, Animal immunology, Transcription and translation, Vaccines, Molecular and cell biology not elsewhere classified, Virology
- See also: Xavier Saelens (Flanders Institute for Biotechnology)
Affiliations
- Department of Biochemistry and microbiology (Department)
Member
From1 Oct 2018 → Today - Saelens Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Biomedical molecular biology (Department)
Member
From1 Jan 1996 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Jan 1993 → 31 Dec 1995
Projects
1 - 10 of 21
- Development of intrabody-expressing influenza virus vectors to discover new pro- and antiviral host factorsFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- New antivirals against human parainfluenza virusFrom1 Apr 2023 → TodayFunding: IOF - technology validation in lab
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Prepared for SARS-CoV-3: advancing our understanding of SARS coronavirus antigenic and pathogenic evolutionFrom1 Jan 2022 → TodayFunding: FWO EOS
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases.From1 Nov 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseasesFrom1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- A nanobody-based anti-inflammatory treatment against pathogen-induced chronic lung inflammationFrom1 Oct 2021 → TodayFunding: BOF - projects
- Designed, broadly protective antibodies directed against influenza B.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- mRNA Lipid nanoparticles co-loaded with alpha-Galactosylceramide as a universal influenza vaccine platformFrom1 Oct 2020 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Prophylaxis of at risks persons with an ultrapotent SARS-CoV-2-neutralizing antibodyFrom22 May 2020 → 31 May 2021Funding: FWO Special Call for Covid-19 research projects
Publications
1 - 10 of 39
- Epidemiology of influenza over a ten-year period in Belgium : overview of the historical and current evidence(2023)
Authors: Andrea Prezzi, Xavier Saelens, Dominique Vandijck
- Rethinking IL-1 antagonism in respiratory viral infections : a role for IL-1 signaling in the development of antiviral T cell immunity(2023)
Authors: Bram Van Den Eeckhout, Marlies Ballegeer, Jozefien De Clercq, Elianne Burg, Xavier Saelens, Linos Vandekerckhove, Sarah Gerlo
- ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection(2022)
Authors: Mohammad Arabpour, Cristina Lebrero-Fernandez, Karin Schön, Anneli Strömberg, Vanja Börjesson, Katharina Lahl, Marlies Ballegeer, Xavier Saelens, Davide Angeletti, William Agace, et al.
Pages: 745 - 761 - Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase(2022)
Authors: João Paulo Portela Catani, Emma Job, Tine Ysenbaert, Anouk Smet, Satyajit Ray, Lauren LaRue, Svetlana Stegalkina, Mario Barro, Thorsten U. Vogel, Xavier Saelens
- A general approach to identify low-frequency variants within influenza samples collected during routine surveillance(2022)
Authors: Laura Van Poelvoorde, Thomas Delcourt, Marnik Vuylsteke, Sigrid C. J. De Keersmaecker, Isabelle Thomas, Steven Van Gucht, Xavier Saelens, Nancy Roosens, Kevin Vanneste
- Strategy and performance evaluation of low-frequency variant calling for SARS-CoV-2 using targeted deep Illumina sequencing(2021)
Authors: Laura Van Poelvoorde, Thomas Delcourt, Wim Coucke, Philippe Herman, Sigrid C. J. De Keersmaecker, Xavier Saelens, Nancy H. C. Roosens, Kevin Vanneste
- Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity(2021)
Authors: Fabien Henri Thery, Lia Martina, Caroline Asselman, Heidi Repo, Y Zhang, Koen Sedeyn, Georgios Moschonas, C Bredow, QW Teo, J Zhang, et al.
- Reverse engineering synthetic antiviral amyloids(2020)
Authors: Emiel Michiels, Kenny Roose, Rodrigo Gallardo, Ladan Khodaparast, Laleh Khodaparast, Rob van der Kant, Maxime Siemons, Bert Houben, Meine Ramakers, Hannah Wilkinson, et al.
- Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation(2020)
Authors: Laurens Raes, Stephan Stremersch, Juan Fraire, Toon Brans, Glenn Goetgeluk, Stijn De Munter, Lien Van Hoecke, Rein Verbeke, Jelter Van Hoeck, Ranhua Xiong, et al.
- TIV vaccination modulates host responses to influenza virus infection that correlate with protection against bacterial superinfection(2019)
Authors: Angela Choi, Ioanna Christopoulou, Xavier Saelens, Adolfo García-Sastre, Michael Schotsaert
Patents
1 - 9 of 9
- CORONA VIRUS BINDERS (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- Anti-influenza antibody (Inventor)
- SINGLE DOMAIN ANTIBODY AGAINST RSV F PROTEIN (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- RESPIRATORY SYNCYTICAL VIRUS VACCINE (Inventor)
- Anti-influenza antibody (Inventor)